SiNtx Technologies (SINT) Earnings Date & Reports

Key Takeaways

• SINTX Technologies reported third-quarter 2026 revenue of approximately $2.2 million, up 953% from $208,000 a year earlier, driven by aerospace technical manufacturing sales.
• Gross profit climbed to roughly $1.4 million, with gross margin expanding to 62% from 45% in the prior-year quarter.
• Net loss narrowed 55% to about $1.6 million, while operating expenses declined 13% to approximately $3.0 million.
• GAAP (Generally Accepted Accounting Principles) net loss per share came in at $0.24, narrower than analyst consensus estimates, with revenue topping expectations.
• The company regained compliance with Nasdaq's minimum stockholders' equity requirement and received roughly $2.0 million from the exercise of Class B warrants.
• Get more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Explore Trending AI Robots to see how AI-driven trading strategies are scanning the market right now.

Earnings Context and Why It Matters

SINTX Technologies is an advanced biomaterials and ceramics company commercializing proprietary silicon nitride across medical and industrial applications. For years, the company has operated with minimal revenue and persistent losses, making each quarterly report a test of whether its manufacturing and commercialization strategy can translate into sustained financial progress. The third quarter of 2026 carries added weight because it represents the first full quarter reflecting shipments against the more than $3.2 million in contract manufacturing purchase orders announced in June. Investors are watching closely to determine whether the company can convert order flow into recognized revenue, expand gross margin, and reduce cash burn as it pivots toward commercial scale.

Reported Results

For the third quarter ended September 30, 2026, SINTX reported total revenue of approximately $2.2 million, a 953% increase from $208,000 in the prior-year period. Product revenue was $2.1 million, up from $150,000 a year earlier, with the growth driven primarily by aerospace technical manufacturing sales to Fortune 500 customers. Grant and contract revenue was $100,000, compared with $58,000 in the prior-year quarter.

Gross profit rose to approximately $1.4 million from $93,000 a year ago, and gross margin expanded to 62% from 45%, helped by pricing adjustments, favorable product mix, and higher production volumes. Total operating expenses fell 13% to about $3.0 million, and the net loss narrowed 55% to roughly $1.6 million from $3.5 million. On a per-share basis, the company posted a GAAP net loss of $0.24, narrower than the consensus estimate of about $0.34 per share, while revenue of $2.2 million topped the consensus estimate of roughly $0.9 million.

On the balance sheet, cash and cash equivalents stood at approximately $2.0 million at quarter-end, down from $4.1 million at the end of 2025, reflecting operating cash use and working capital investment. The company subsequently received about $2.0 million from the exercise of Class B warrants and regained compliance with Nasdaq's minimum stockholders' equity requirement.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following names like SINTX Technologies, it offers a structured way to surface potential setups across the broader market.

Market Reaction and Investor Sentiment

Sentiment heading into the report had already improved after the company's October 1 preliminary announcement revealed $2.2 million in third-quarter revenue, far above its prior guidance range of $0.9 million to $1.1 million. The confirmed results reinforced that momentum, with revenue, gross margin, and the narrowed loss all exceeding consensus expectations. Still, investor interpretation remains measured: the company continues to report losses and ended the quarter with about $2.0 million in cash, underscoring ongoing liquidity and financing considerations. The regained Nasdaq listing compliance and the warrant exercise proceeds provided some balance-sheet relief, but execution risk around converting further purchase orders into recognized revenue remains a central focus for the market.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is fourth-quarter revenue, where management reiterated a guidance range of approximately $1.0 million to $1.3 million. Because the timing and size of customer orders can cause meaningful quarterly swings, investors should track whether the company continues converting its remaining contract manufacturing purchase orders into recognized revenue on schedule.

Margin sustainability is another key factor. The 62% gross margin reflected favorable mix, pricing, and production volumes, but management has cautioned that margins can vary from quarter to quarter based on product mix and demand. Watching whether margins hold as the industrial business scales will help clarify the durability of recent improvements.

Finally, liquidity and financing remain central to the story. With cash of roughly $2.0 million at quarter-end and ongoing operating losses, the company's ability to fund working capital and commercialization without overly dilutive capital raises is a critical monitorable. Progress on the SiNAPTIC Foot & Ankle Osteotomy Wedge System and the silicon nitride-treated medical textile studies also represent longer-term growth avenues worth following.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations